-
Regeneron Is 'One Of The Stronger Growers In Biotech'
Wednesday, June 29, 2016 - 3:04pm | 416Read More...Bernstein has initiated coverage of Regeneron Pharmaceuticals Inc (NASDAQ: REGN) with an Outperform rating and $400 price target, citing a "good entry point for one of stronger growers in biotech." "Regeneron is a growth-phase biopharma with one large successful first product (Eylea) and two...
-
Regeneron Gains 4% Following Q1 Earnings Release
Thursday, May 5, 2016 - 8:53am | 348Read More...Shares of Regeneron Pharmaceuticals Inc (NASDAQ: REGN) were trading higher by more than 4 percent early Thursday morning after the company reported its first-quarter results. Regeneron said that it earned $2.57 per share in the first quarter on revenue of $1.2 billion. Wall Street analysts were...
-
Regeneron Pharmaceuticals Loses 7% Following Q4 Miss
Tuesday, February 9, 2016 - 9:18am | 312Read More...Shares of Regeneron Pharmaceuticals Inc (NASDAQ: REGN) were trading lower by around 7 percent early Tuesday morning after the company reported its fourth quarter results. Regeneron Pharmaceuticals said that it earned $2.83 per share in the fourth quarter on revenue of $1.16 billion. Wall Street...
-
Chardan Downgrades Regeneron Pharmaceuticals, Notes Valuation Concerns
Monday, August 31, 2015 - 1:31pm | 362Read More...Gbola Amusa, Chardan Capital Markets' head of healthcare research, commented in a note on Monday that investors should be "more selective" in the biotech space. As such, the analyst downgraded shares of Regeneron Pharmaceuticals Inc (NASDAQ: REGN) to Neutral from Buy with an unchanged $565 price...
-
Why Avalanche Biotechnologies Is Coming Off A Big Day
Thursday, June 11, 2015 - 9:10am | 340Read More...Shares of Avalanche Biotechnologies Inc (NASDAQ: AAVL) closed up more than 7 percent on Wednesday following positive commentary by TheStreet.com. According to author Alfredo Fontanini, the company is approaching an important clinical trial catalyst. Results from a phase IIa study of Avalanche's...
-
Regeneron Earnings: Small Growth Expected, Driven By Eylea
Wednesday, May 6, 2015 - 5:30pm | 385Read More...Regeneron Pharmaceuticals Inc (NASDAQ: REGN) is scheduled to announce its first quarter financial results on Thursday, and both the crowd and experts expect to see some growth, although the Street is slightly more bullish. According to Estimize, Wall Street analysts model consensus earnings of...
-
UPDATE: Barclays Initiates Coverage On Regeneron
Tuesday, January 6, 2015 - 12:28pm | 200Read More...Geoffrey Meacham of Barclays initiated coverage of Regeneron Pharmaceuticals Inc (NASDAQ: REGN) on Tuesday with an Equal-Weight rating and $450 price target as approval and modest growth profile of key drugs are already expected by investors. Based on Meacham's survey of 50 U.S....
-
Markets Marginally Higher On Light Volume And Encouraging Geopolitical Developments
Monday, August 11, 2014 - 4:46pm | 2480Read More...U.S. markets managed to squeeze out small gains in lighter than normal volume, as geopolitical tensions may be calming down. Russia President Vladimir Putin said that the country will coordinate with the International Red Cross to send humanitarian aid to Ukraine. Meanwhile, Palestinians and...
-
Top Trending Tickers On StockTwits For February 11
Tuesday, February 11, 2014 - 12:10pm | 1034Read More...Here's a look at the top tickers trending on StockTwits.com Regeneron: Net profit lower, sees Eylea growth This morning, Regeneron Pharmaceuticals (NASDAQ: REGN) reported its fourth quarter results. The company announced an EPS of $2.24, beating the consensus estimate of $2.08. Revenue of $...
